Elsilimomab

Elsilimomab (also known as B-E8) is a mouse monoclonal antibody[1] and an immunosuppressive drug. B-E8 was developed by Diaclone,[2] a French company which produces many mouse monoclonal antibodies.

Elsilimomab

Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	IL-6
Clinical data
ATC code	none
Identifiers
CAS Number	468715-71-1^N
ChemSpider	none
^NY (what is this?)  (verify)

It (OPR-003) targets (and blocks) Interleukin-6.[3]

It has undergone a number of early stage clinical trails, e.g. for lymphoma and myeloma.[4]

It was used as a template to develop a high-affinity, antagonist, fully human anti-IL-6 mAb 1339.[4]

References

1. "WHO Drug Information" (PDF). p11:immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 k-chain, dimer
2. "Datasheet B-E8 mAb". Diaclone.
3. "First Fully Human Anti-IL6 Antibody Under Development". Genetic Engineering & Biotechnology News. Oct 2006.
4. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, et al. (December 2009). "A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma". Clinical Cancer Research. 15 (23): 7144–52. doi:10.1158/1078-0432.CCR-09-1483. PMC 2787636. PMID 19934301.